Zai Lab (ZLAB) – Analysts’ Recent Ratings Changes

Zai Lab (NASDAQ: ZLAB) has recently received a number of price target changes and ratings updates:

• 5/22/2026 – Zai Lab was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/16/2026 – Zai Lab was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/11/2026 – Zai Lab was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/8/2026 – Zai Lab had its price target lowered by Citigroup Inc. from $47.00 to $44.00. They now have a “buy” rating on the stock.
• 4/24/2026 – Zai Lab was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In other Zai Lab news, insider Joshua L. Smiley sold 9,614 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total transaction of $196,029.46. Following the completion of the transaction, the insider owned 120,619 shares of the company’s stock, valued at $2,459,421.41. This represents a 7.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Yajing Chen sold 5,199 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total value of $106,007.61. Following the completion of the transaction, the chief financial officer directly owned 32,558 shares of the company’s stock, valued at $663,857.62. This represents a 13.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 96,187 shares of company stock worth $1,935,147. 4.88% of the stock is currently owned by company insiders.

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.